A 3D View of evidence-based Management of Advanced Gastric Cancer and Gastroesophageal Junction Cancer: How to Combine/Sequence Chemotherapy and New Targeted Agents in an Era of Personalized Care
This program is free of charge to host at your institution, and is completely free of bias and promotional content. MLG will provide the accreditation, content, faculty, meeting materials, and audio visual services if needed.
April 2018 – December 2018
This case-based live activity will cover the diagnosis, treatment, and management of patients with Gastric Cancer.
- Assess both monotherapy and combination regimens that have demonstrated efficacy in advanced and metastatic gastric and gastroesophageal junction cancers across all lines of therapy
- Review medical society guidelines for the treatment of advanced gastric cancer and gastroesophageal junction cancer from first line through subsequent lines of treatment
- Describe the development of treatment strategies and the management of adverse events to optimize efficacy and quality of life in the care of patients with advanced GC and GEJ
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with Gastric Cancer.
1.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at email@example.com
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.